Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?

Pfizer shares have risen 8.6% over three months and reached a 52-week high on Sept. 3 as non-COVID revenue grew 5% operationally and recently launched/acquired products increased 18% in Q2 2026. However, Pfizer's 2026 revenue guidance of $60.5B-$62.5B implies flat to slightly lower sales versus $62.6B in 2025, while adjusted EPS guidance of $2.80-$3.00 is below 2025's $3.22 amid lower COVID demand and acquisition dilution. COVID revenue is expected to fall to about $4B in 2026 from $6.7B in 2025, and patent expirations are projected to reduce 2026 sales by roughly $1.1B; management is relying on oncology, obesity pipeline assets and $9.7B of productivity savings through 2029 to restore growth.

Analysis

PFE’s rerating is constrained by an earnings-quality problem rather than simply a revenue-growth problem: cost actions can protect near-term EPS, but they do not establish that acquired and launched assets can earn returns above the capital deployed. The market is likely to assign only a modest multiple expansion until management demonstrates durable organic growth excluding deal contributions and avoids further dilution from business development. The key 1-3 month catalyst is whether the next earnings report converts operational growth into a higher 2027 earnings floor; absent that, the recent strength is vulnerable to a value-trap reset.

The non-obvious competitive risk is that PFE’s oncology ambition requires substantial commercial and trial spend precisely as mature-product cash flows weaken. In ADCs and PD-(L)1/VEGF combinations, clinical differentiation—not pipeline breadth—will determine value; disappointing efficacy or tolerability from pivotal programs would impair the strategic case for the Seagen platform and pressure R&D returns. AZN and ABBV have less need to prove a portfolio transition, while BNTX has asymmetric downside if the shared COVID franchise continues to contract faster than its oncology pipeline matures.

Obesity should not yet be capitalized as a material PFE earnings driver. A 2028-oriented program leaves PFE exposed to a moving standard of care, pricing pressure, and capacity advantages held by LLY and NVO; by launch, efficacy thresholds may be materially higher than today. Conversely, a credible monthly dosing profile with competitive weight-loss and discontinuation data could create option value well before approval, making clinical readouts—not current sales estimates—the relevant catalyst.

Consensus may be underestimating the dividend’s role as a valuation floor but overestimating its ability to offset execution risk. At a low earnings multiple, PFE does not need exceptional growth to work; it needs repeated proof that launch revenues and productivity savings exceed erosion. Thesis is falsified by a cut to the 2027 EPS outlook, launch/ acquired-product growth decelerating below low-double-digits, or incremental debt-funded M&A before leverage declines.

Key Decisions for Investors

• Maintain a tactical long PFE only on pullbacks, sized as a 6-12 month value/carry position rather than a growth position. Target a rerating toward 10.5-11x forward EPS if 2027 EPS expectations rise; exit if forward EPS falls below $2.85 or management signals another material acquisition.
• Implement a relative-value pair: long PFE / short ABBV in equal dollar beta-adjusted size over 3-6 months only if PFE’s next results reaffirm launch-asset growth and ABBV’s forward estimates remain unchanged. The trade captures PFE’s lower valuation and carry, but stop out if the PFE/ABBV relative-price ratio breaks 10% below entry because AbbVie’s Skyrizi/Rinvoq execution is structurally stronger.
• Do not rotate from LLY or NVO into PFE solely on obesity optionality. Establish an alert for PFE’s berobenatide Phase II combination data and early Phase III discontinuation/weight-loss benchmarks; consider long PFE calls only after data show competitive efficacy with a tolerability advantage, since pre-data valuation assigns little but not zero pipeline value.
• Avoid BNTX as a COVID-revenue hedge against PFE: the shared franchise decline is directionally adverse to both, while BNTX’s valuation depends more heavily on oncology clinical validation. Reassess BNTX only around independent oncology readouts rather than seasonal vaccine demand.